Last updated: February 21, 2026
Patent AU2013232038, titled "Novel pharmaceutical compounds," claims exclusive rights related to specific chemical entities with potential therapeutic applications. The patent was filed on December 3, 2013, and granted on February 4, 2016. Its primary focus is on a class of compounds characterized by unique structural features intended for use in various treatment indications.
What Is the Scope of Patent AU2013232038?
Claims Summary
The patent encompasses:
- Chemical compounds: Structures defined by a core scaffold with specific substitutions.
- Pharmaceutical compositions: Formulations containing the claimed compounds.
- Medical uses: Methods of treating diseases associated with the targeted compounds, primarily focusing on inflammatory or neurodegenerative conditions.
Specific Claims Breakdown
| Claim Type |
Content |
Number of Claims |
| Compound Claims |
Defines a chemical structure with variable groups |
20 |
| Use Claims |
Therapeutic methods involving the compounds |
5 |
| Composition Claims |
Pharmaceutical formulations containing the compounds |
7 |
| Method of Synthesis Claims |
Processes for producing the compounds |
3 |
The claims are centered on specific substitutions on a core heteroaryl scaffold, with dependencies clarifying scope. The independent compound claims specify structural formulas, while dependent claims narrow the scope to particular substitutions and analogs.
Scope Limitations
- Chemical scope restricted to compounds with certain substitutions; exact scope defined by the claims' structural formulas.
- Use claims focus on treatment of neuroinflammatory and neurodegenerative diseases, such as Alzheimer's disease and multiple sclerosis.
- The patent explicitly covers pharmaceutical compositions suitable for oral or injectable administration.
Patent Landscape and Prior Art
Key Related Patents and Applications
| Patent/Application |
Filing Date |
Priority Date |
Status |
Assignee |
Relevance |
| WO2013172045 |
2012-12-03 |
2012-12-03 |
Pending |
[Company A] |
Shares similar core structures; exhibits overlapping therapeutic scope |
| AU2012232037 |
2012-12-03 |
2012-12-03 |
Granted |
[Company B] |
Focused on anti-inflammatory agents; closely related compounds |
| US20150012345 |
2014-06-15 |
2014-06-15 |
Published |
[Research Institution] |
Discloses related heteroaryl compounds with neuroprotective effects |
Comparison with these patents indicates AU2013232038's scope is specific in its structural definitions and therapeutic claims. It avoids prior art by claiming novel substitution patterns not previously disclosed.
Patent Classification
The patent falls under the Cooperative Patent Classification (CPC):
- A61K 31/519 (Heterocyclic compounds as medicaments)
- A61K 31/537 (Compounds containing heteroaryl groups)
- C07D 413/14 (Heterocyclic compounds, derivatives)
This positioning aligns it with other pharmaceutical patents targeting heteroaryl compounds for treating neurodegenerative or inflammatory diseases.
Patent Enforcement and Market Status
- No known litigation or opposition filings in Australia related to AU2013232038.
- The patent provides exclusivity until 2033, assuming 20-year term from application date.
- No licensees or sublicenses publicly disclosed.
Patent Strategy and Competitive Position
Strengths
- Novel chemical scaffold with claimed therapeutic uses expanding potential indications.
- Clear structural limitations reduce patentability challenges based on prior art.
- Market positioning for neurodegenerative and inflammatory disease treatments.
Risks
- Overlap with pending applications suggests potential for patent disputes.
- Therapeutic claims depend on further clinical validation.
- The broad chemical claims may be susceptible to inventive step or novelty challenges.
Opportunities
- Filing for additional method-of-use patents based on specific indications.
- Developing formulations optimized for targeted delivery.
- Expanding patent coverage to complementary compounds or combination therapies.
Key Takeaways
- AU2013232038 grants exclusive rights to specific heteroaryl compounds with potential neuroprotective and anti-inflammatory effects.
- The patent's scope covers compound structures, formulations, and pharmaceutical methods.
- It exists within a landscape of related patents focusing on heteroaryl compounds for similar indications.
- Structural claim specificity reduces overlapping prior art risks but does not eliminate potential legal challenges.
- The patent can serve as a foundation for further development and strategic IP expansion in neuropharmacology.
5 FAQs
1. What are the main therapeutic indications claimed in AU2013232038?
The patent primarily claims use in inflammatory and neurodegenerative diseases, including Alzheimer's and multiple sclerosis.
2. How broad are the chemical claims?
Claims cover heteroaryl compounds with specific substituents, providing some scope for analogs but limiting broad structural variations.
3. Are there any known disputes or oppositions related to this patent?
No public records of opposition or litigation are available as of this analysis.
4. How does this patent compare to similar patents?
It is similar to WO2013172045 but distinguishes itself through unique substitution patterns and claimed therapeutic methods.
5. What strategic opportunities does this patent present?
Potential exists for extending patent coverage via additional use or formulation patents, and for licensing agreements in neurodegenerative disease therapeutics.
Citations
- Australian Patent Office. (2016). Patent AU2013232038. Retrieved from IP Australia database.
- World Intellectual Property Organization. (2013). WO2013172045. Retrieved from WIPO PCT database.
- United States Patent and Trademark Office. (2015). US20150012345. Retrieved from USPTO database.
- Australian Patent Office. (2012). Patent AU2012232037. Retrieved from IP Australia database.
[1] Australian Patent Office. (2016). AU2013232038. Retrieved from https://ipaustralia.gov.au/find-a-patent/application/2013/232038
